The absence of monocyte and pDC activation by IFNα ex vivo could explain the lack of an in vivo anti-leukemic effect, and the therapeutic effect of IFNα may potentially be enhanced by removing this inherent block of activation in healthy immune subsets in AML patients. The gene discussed is IFNA1; the disease is acute myeloid leukemia.